Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque
Abstract
:1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- European Comission EUROSTAT. Causes and Occurrence of Deaths in the EU. Available online: https://ec.europa.eu/eurostat/web/products-eurostat-news/product/-/asset_publisher/VWJkHuaYvLIN/content/DDN-20190716-1/pop_up (accessed on 16 July 2019).
- Ross, R. Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 1998, 340, 115–126. [Google Scholar] [CrossRef] [PubMed]
- Young, J.L.; Libby, P.; Schonbeck, U. Cytokines in the pathogenesis of atherosclerosis. Thromb. Haemost. 2002, 88, 554–567. [Google Scholar] [CrossRef] [PubMed]
- Golledge, J.; Greenhalgh, R.M.; Davies, A.H. The symptomatic carotid plaque. Stroke 2000, 31, 774–781. [Google Scholar] [CrossRef] [Green Version]
- Hansson, G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352, 1685–1695. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Laurent, S.; Cockcroft, J.; Van Bortel, L.; Boutouyrie, P.; Giannattasio, C.; Hayoz, D.; Pannier, B.; Vlachopoulos, C.; Wilkinson, I.; Struijker-Boudier, H.; et al. Expert consensus document on arterial stiffness: Methodologicalissues and clinical applications. Eur. Heart J. 2006, 27, 2588–2605. [Google Scholar] [CrossRef] [Green Version]
- Shalhoub, J.; Owen, D.R.; Gauthier, T.; Monaco, C.; Leen, E.L.; Davies, A.H. The use of contrast enhanced ultrasound in carotid arterial disease. Eur. J. Vasc. Endovasc. Surg. 2010, 39, 381–387. [Google Scholar] [CrossRef] [Green Version]
- Yazdani, S.K.; Vorpahl, M.; Ladich, E.; Virmani, R. Pathology and vulnerability of atherosclerotic plaque: Identification, treatment options, and individual patient differences for prevention of stroke. Curr. Treat. Options Cardiovasc. Med. 2010, 12, 297–314. [Google Scholar] [CrossRef]
- Thim, T.; Hagensen, M.K.; Bentzon, J.F.; Falk, E. From vulnerable plaque to atherothrombosis. J. Intern. Med. 2008, 263, 506–516. [Google Scholar] [CrossRef]
- Naghavi, M.; Libby, P.; Falk, E.; Casscells, S.W.; Litovsky, S.; Rumberger, J.; Badimon, J.J.; Stefanadis, C.; Moreno, P.; Pasterkamp, G.; et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108, 1664–1672. [Google Scholar] [CrossRef]
- Lessner, S.M.; Galis, Z.S. Matrix metalloproteinases and vascular endothelium-mononuclear cell close encounters. Trends Cardiovasc. Med. 2004, 14, 105–111. [Google Scholar] [CrossRef]
- Choudhary, S.; Higgins, C.L.; Chen, I.Y.; Reardon, M.; Lawrie, G.; Vick, G.W., 3rd; Karmonik, C.; Via, D.P.; Morrisett, J.D. Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissues. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 2351–2358. [Google Scholar] [CrossRef] [Green Version]
- Zouridakis, E.; Avanzas, P.; Arroyo-Espliguero, R.; Fredericks, S.; Kaski, J.C. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004, 110, 1747–1753. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Heinegard, D.; Hultenby, K.; Oldberg, A.; Reinholt, F.; Wendel, M. Macromolecules in bone matrix. Connect Tissue Res. 1989, 21, 3–11. [Google Scholar] [CrossRef] [PubMed]
- Wexler, L.; Brundage, B.; Crouse, J.; Detrano, R.; Fuster, V.; Maddahi, J.; Rumberger, J.; Stanford, W.; White, R.; Taubert, K. Coronary artery calcification: Pathophysiology epidemiology imaging methods and clinical implications: A statement for health professionals from the American Heart Association. Circulation 1996, 94, 1175–1192. [Google Scholar] [CrossRef] [PubMed]
- Ashkar, S.; Weber, G.F.; Panoutsakopoulou, V.; Sanchirico, M.E.; Jansson, M.; Zawaideh, S.; Rittling, S.R.; Denhardt, D.T.; Glimcher, M.J.; Cantor, H. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 2000, 287, 860–864. [Google Scholar] [CrossRef] [PubMed]
- Giachelli, C.M.; Bae, N.; Almeida, M.; Denhardt, D.T.; Alpers, C.E.; Schwartz, S.M. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Investig. 1993, 92, 1686–1696. [Google Scholar] [CrossRef] [Green Version]
- Ikeda, T.; Shirasawa, T.; Esaki, Y.; Yoshiki, S.; Hirokawa, K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J. Clin. Investig. 1993, 92, 2814–2820. [Google Scholar] [CrossRef] [Green Version]
- Ohmori, R.; Momiyama, Y.; Taniguchi, H.; Takahashi, R.; Kusuhara, M.; Nakamura, H.; Ohsuzu, F. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003, 170, 333–337. [Google Scholar] [CrossRef]
- Hofbauer, L.C.; Khosla, S.; Dunstan, C.R.; Lacey, D.L.; Boyle, W.J.; Riggs, B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 2000, 15, 2–12. [Google Scholar] [CrossRef]
- Hofbauer, L.C.; Shui, C.; Riggs, B.L.; Dunstan, C.R.; Spelsberg, T.C.; O’Brien, T.; Khosla, S. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem. Biophys. Res. Commun. 2001, 280, 334–339. [Google Scholar] [CrossRef]
- Price, P.A.; June, H.H.; Buckley, J.R.; Williamson, M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1610–1616. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Malyankar, U.M.; Scatena, M.; Suchland, K.L.; Yun, T.J.; Clark, E.A.; Giachelli, C.M. Osteoprotegerin is an AvB3-induced, NF-KB-dependent survival factor for endothelial cells. J. Biol. Chem. 2000, 275, 20959–20962. [Google Scholar] [CrossRef] [Green Version]
- Kadoglou, N.; Kottas, G.; Lampropoulos, S.; Vitta, I.; Liapis, C. Serum Levels of Fetuin-A, Osteoprotegerin and Osteopontin in Patients with Coronary Artery Disease: Effects of Statin (HMGCoA-Reductase Inhibitor) Therapy. Clin. Drug Investig. 2014, 34, 165–171. [Google Scholar] [CrossRef] [PubMed]
- Fujimoto, S.; Hartung, D.; Ohshima, S.; Edwards, D.S.; Zhou, J.; Yalamanchili, P.; Azure, M.; Fujimoto, A.; Isobe, S.; Matsumoto, Y.; et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: Resolution with dietary modification and statin therapy. J. Am. Coll. Cardiol. 2008, 52, 1847–1857. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stein, E.A.; Gipe, D.; Bergeron, J.; Gaudet, D.; Weiss, R.; Dufour, R.; Wu, R.; Pordy, R. Effects of a monoclonal antibody to PCSK 9 Reg N 727/SAR 236553 to reduce low density lipoprotein cholesterol in patients with heterozygous familial hypercholestremia on stable statin dose with or without ezetimibe therapy: A phase 2 randomized controlled trial. Lancet 2012, 380, 29–36. [Google Scholar]
- Basiak, M.; Kosowski, M.; Cyrnek, M.; Bułdak, Ł.; Maligłówka, M.; Machnik, G.; Okopień, B. Pleiotropic Effects of PCSK-9 Inhibitors. Int. J. Mol. Sci. 2021, 22, 3144. [Google Scholar] [CrossRef]
- Moriarty, P.M.; Jacobson, T.A.; Bruckert, E.; Thompson, P.D.; Guyton, J.R.; Baccara-Dinet, M.T.; Gipe, D.I. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK-9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J. Clin. Lipidol. 2014, 8, 554–561. [Google Scholar] [CrossRef] [Green Version]
- Abedin, M.; Tintut, Y.; Demer, L.L. Vascular calcification: Mechanisms and clinical ramifications. Arterioscler. Thromb. Vasc. Biol 2004, 24, 1161–1170. [Google Scholar] [CrossRef]
- Kadoglou, N.P.; Gerasimidis, T.; Golemati, S.; Kapelouzou, A.; Karayannacos, P.E.; Liapis, C.D. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J. Vasc. Surg. 2008, 47, 55–62. [Google Scholar] [CrossRef] [Green Version]
- Van Campenhout, A.; Golledge, J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009, 204, 321–329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Siasos, G.; Tousoulis, D.; Kioufis, S.; Oikonomou, E.; Siasou, Z.; Limperi, M.; Papavassiliou, A.G.; Stefanadis, C. Inflammatory mechanisms in atherosclerosis: The impact of matrix metalloproteinases. Curr. Top. Med. Chem. 2012, 12, 1132–1148. [Google Scholar] [CrossRef] [PubMed]
- Amin, M.; Pushpakumar, S.; Muradashvili, N.; Kundu, S.; Tyagi, S.C.; Sen, U. Regulation and involvement of matrix metalloproteinases in vascular diseases. Front. Biosci. (Landmark Ed.) 2016, 21, 89–118. [Google Scholar] [PubMed] [Green Version]
- Vasků, A.; Goldbergová, M.; Izakovicov Hollá, L.; Sisková, L.; Groch, L.; Beránek, M.; Tschöplová, S.; Znojil, V.; Vácha, J. A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease. Matrix Biol. 2004, 22, 585–591. [Google Scholar] [CrossRef]
- Luizon, M.R.; Belo, V.A.; Fernandes, K.S.; Andrade, V.L.; Tanus-Santos, J.E.; Sandrim, V.C. Plasma matrix metalloproteinase-9 levels, MMP-9 gene haplotypes, and cardiovascular risk in obese subjects. Mol. Biol. Rep. 2016, 43, 463–471. [Google Scholar] [CrossRef] [Green Version]
- Shirakawa, K.; Sano, M. Osteopontin in Cardiovascular Diseases. Biomolecules 2021, 11, 1047. [Google Scholar] [CrossRef]
- Huang, Q.X.; Li, J.B.; Huang, N.; Huang, X.W.; Li, Y.L.; Huang, F.X. Elevated Osteoprotegerin Concentration Predicts Increased Risk of Cardiovascular Mortality in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Kidney Blood Press. Res. 2020, 45, 565–575. [Google Scholar] [CrossRef] [PubMed]
- Albert, M.A.; Danielson, E.; Rifai, N.; Ridker, P.M.; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001, 286, 64–70. [Google Scholar] [CrossRef] [PubMed]
- Goettsch, C.; Hutcheson, J.D.; Hagita, S.; Rogers, M.A.; Creager, M.D.; Pham, T.; Choi, J.l.; Mlynarchik, A.K.; Pieper, B.; Kjolby, M.; et al. A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification. Atherosclerosis 2016, 251, 109–118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hwang, H.S.; Kim, J.S.; Kim, Y.G.; Lee, S.Y.; Ahn, S.Y.; Lee, H.J.; Lee, D.Y.; Lee, S.H.; Moon, J.Y.; Jeong, K.H. Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients. J. Clin. Med. 2020, 9, 244. [Google Scholar] [CrossRef] [Green Version]
- Lupo, M.G.; Bressan, A.; Donato, M.; Canzano, P.; Camera, M.; Poggio, P.; Greco, M.F.; Garofalo, M.; De Martin, S.; Panighel, G.; et al. PCSK9 promotes arterial medial calcification. Atherosclerosis 2022, 346, 86–97. [Google Scholar] [CrossRef]
- Golia, E.; Limongelli, G.; Natale, F.; Fimiani, F.; Maddaloni, V.; Pariggiano, I.; Bianchi, R.; Crisci, M.; D’Acierno, L.; Giordano, R.; et al. Inflammation and cardiovascular disease: From pathogenesis to therapeutic target. Curr. Atheroscler. Rep. 2014, 16, 435. [Google Scholar] [CrossRef] [PubMed]
- Guo, H.; Shi, Y.; Liu, L.; Sun, A.; Xu, F.; Chi, J. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Arch. Med. Res. 2009, 40, 345–351. [Google Scholar] [CrossRef] [PubMed]
- Shirakabe, A.; Asai, K.; Hata, N.; Yokoyama, S.; Shinada, T.; Kobayashi, N.; Tomita, K.; Tsurumi, M.; Matsushita, M.; Mizuno, K. Immediate administration of atorvastatin decreased the serum MMP-2 level and improved the prognosis for acute heart failure. J. Cardiol. 2012, 59, 374–382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kadoglou, N.P.; Sailer, N.; Moumtzouoglou, A.; Kapelouzou, A.; Gerasimidis, T.; Liapis, C.D. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. J. Vasc. Surg. 2010, 51, 114–121. [Google Scholar] [CrossRef]
- Andrade, V.L.; do Valle, I.B.; Sandrim, V.C. Simvastatin therapy decreases MMP-9 levels in obese women. J. Clin. Pharmacol. 2013, 53, 1072–1077. [Google Scholar] [CrossRef]
- Ridker, P.M. Mortality differences associated with treatment responses in CANTOS and FOURIER: Insight and implications. Circulation 2018, 137, 1763–1766. [Google Scholar] [CrossRef]
- Cheng, J.M.; Oemrawsingh, R.M.; Garcia-Garcia, H.M.; Boersma, E.; van Geuns, R.J.; Serruys, P.W.; Kardys, I.; Akkerhuis, K.M. PCSK-9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis 2016, 248, 117–122. [Google Scholar] [CrossRef]
- Omori, H.; Ota, H.; Hara, M.; Kawase, Y.; Tanigaki, T.; Hirata, T.; Sobue, Y.; Okubo, M.; Kamiya, H.; Matsuo, H.; et al. Effect of PCSK-9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaque Assessed by Near-Infrared Spectroscopy. Cardiovasc. Imaging 2020, 13, 1639–1641. [Google Scholar] [CrossRef]
- Elseweidy, M.M.; Mohamed, H.E.; Elrashidy, R.A.; Atteia, H.H.; Elnagar, G.M. Inhibition of Aortic Calcification by Policosanol in Dyslipidemic Rabbits Is Enhanced by Pentoxifylline: Potential Role of PCSK9. J. Cardiovasc. Pharmacol. Ther. 2018, 23, 551–560. [Google Scholar] [CrossRef]
- Otake, H.; Sugizaki, Y.; Toba, T.; Nagano, Y.; Tsukiyama, Y.; Yanaka, K.I.; Yamamoto, H.; Nagasawa, A.; Onishi, H.; Takeshige, R.; et al. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin. J. Cardiol. 2019, 73, 228–232. [Google Scholar] [CrossRef] [Green Version]
- Vallejo-Vaz, A.J.; Leiter, L.A.; Del Prato, S.; Taskinen, M.R.; Müller-Wieland, D.; Bujas-Bobanovic, M.; Letierce, A.; Mandel, J.; Samuel, R.; Ray, K.K. Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. Eur. J. Prev. Cardiol. 2020, 27, 1663–1674. [Google Scholar] [CrossRef] [PubMed]
- Colhoun, H.M.; Leiter, L.A.; Müller-Wieland, D.; Cariou, B.; Ray, K.K.; Tinahones, F.J.; Domenger, C.; Letierce, A.; Israel, M.; Samuel, R.; et al. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovasc. Diabetol. 2020, 19, 14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Clifton, P.M. Diet, exercise and weight loss and dyslipidaemia. Pathology 2019, 51, 222–226. [Google Scholar] [CrossRef] [PubMed]
Control Group | Study Group | |
---|---|---|
Number of patients | 14 | 21 |
Age, years | 45 ± 5 | 47 ± 5 |
Women, % | 35 | 34 |
BMI | 27.5 ± 2.6 | 28.1 ± 2.2 |
Smokers, % | 22 | 24 |
Systolic blood pressure, mmHg | 133 ± 5 | 133 ± 6 |
Diastolic blood pressure, mmHg | 82 ± 4 | 84 ± 4 |
Total cholesterol, mg/dL | 163.4 ± 17.7 | 250.6 ± 35.4 |
LDL cholesterol, mg/dL | 93.5 ± 15.9 | 172.7 ± 30 |
HDL cholesterol, mg/dL | 46.3 ± 5.1 | 40.3 ± 10.1 |
Triglycerides, mg/dL | 121.1 ± 21.1 | 178.4 ± 20.4 |
Fasting glucose, mg/dL | 91 ± 6 | 92 ± 5 |
Control | Study Group before Treatment | Study Group after Treatment | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Mean | SD | Mean | SD | p | ||||||
TC (mg/dL) | 250.6 | 35.4 | 173.8 | 31.6 | <0.001 ** | |||||
LDL (mg/dL) | 172.7 | 30 | 94.4 | 29.1 | <0.001 ** | |||||
HDL (mg/dL) | 40.3 | 10.1 | 49.5 | 10.3 | <0.001 ** | |||||
non-HDL (mg/dL) | 210.3 | 34.2 | 124.3 | 34.9 | <0.001 ** | |||||
Median | Q1 | Q3 | Median | Q1 | Q3 | Median | Q1 | Q3 | ||
TG (mg/dL) | 121.1 | 99.8 | 142.2 | 178.4 | 168 | 198.8 | 142.8 | 123.8 | 157.1 | <0.001 *, <0.001 ** |
TC (mg/dL) | 168.2 | 151.1 | 174.6 | 246.2 | 224.7 | 278.2 | <0.001 * | |||
LDL (mg/dL) | 94.7 | 89.8 | 105.6 | 167.6 | 155.5 | 201.4 | <0.001 * | |||
HDL (mg/dL) | 47.1 | 41.1 | 48.3 | 41 | 34.2 | 43.1 | <0.05 * | |||
non-HDL (mg/dL) | 121.1 | 105.4 | 133.2 | 203.2 | 188.3 | 246.1 | <0.001 * |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kosowski, M.; Basiak, M.; Hachuła, M.; Okopień, B. Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque. Medicina 2022, 58, 969. https://doi.org/10.3390/medicina58070969
Kosowski M, Basiak M, Hachuła M, Okopień B. Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque. Medicina. 2022; 58(7):969. https://doi.org/10.3390/medicina58070969
Chicago/Turabian StyleKosowski, Michał, Marcin Basiak, Marcin Hachuła, and Bogusław Okopień. 2022. "Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque" Medicina 58, no. 7: 969. https://doi.org/10.3390/medicina58070969